

Sreenivasulu N. Pattipati, Ph.D.

Associate Professor of Pharmacology
 Department of Pharmaceutical and Biomedical Sciences
 College of Pharmacy, California Health Sciences University
 120 N. Clovis Avenue, Clovis, CA 93612
 W 559-473-1487 M 559-682-8834
www.chsu.org



EDUCATION AND TRAINING

- 2005-2008** **Postdoctoral Training**
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA
- 2000 - 2004** **Doctor of Philosophy, Ph.D. (Neuropharmacology)**
Faculty of Pharmaceutical Sciences, Panjab University, Chandigarh, India
- 1998-2000** **M.Pharmacy (Pharmacology)**
University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
- 1993-1997** **B.Pharmacy (Gold Medalist)**
University College of Pharmaceutical Sciences, Kakatiya University, Warangal, AP, India
- 1990-1993** **D. Pharmacy (Gold Medalist)**
S.V. Govt Polytechnique, Tirupati, AP, India

ACADEMIC EXPERIANCE

- 2018-** **Associate Professor of Pharmacology**
California Health Sciences University, Clovis, CA, USA
- 2015-2018** **Assistant Professor of Pharmacology**
California Health Sciences University, Clovis, CA, USA
- 2002-2005** **Assistant Professor**
University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
- 1997-1998** **Associate Lecturer**
Nalanda College of Pharmacy, Nalgonda, AP, India

PHARMACEUTICAL INDUSTRY EXPERIENCE (Lead the Team of 18 Ph.D. and MS level Scientists)

- 2013-2015** **Assistant Research Director (Senior Lead Investigator), Disease Sciences and Technology**
Bristol Meyers-Squibb R& D Center, Bangalore, India
Key Accomplishments: as a Discovery working group biology co-chair, identified several lead molecules for multiple discovery programs and played a key role in bringing few molecules to the **Early Clinical Nominee** stage.
- 2011 - 2013** **Lead Investigator, Neuroscience Biology**
Bristol Meyers-Squibb R& D Center, Bangalore, India
Key Accomplishments: as a Discovery working group biology co-chair, identified several lead molecules for multiple discovery programs and played a key role in bringing few molecules to the **Early Clinical Nominee** stage.
- 2008-2011** **Principal Investigator, Neuroscience Biology**
Bristol Meyers-Squibb R& D Center, Bangalore, India
Key accomplishments: Established the state of the art neuroscience lab. Developed and validated multiple animal models in support of discovery programs.

LICENSES

REGISTERED PHARMACIST, INDIA

UNIVERSITY AND PROFESSIONAL COMMITTEE SERVICE

CHSU Environmental Health and Safety Committee	2018-
Research and Scholarship Committee	2016-17, 2018-
Enterprise Risk Management (ERM) Executive Committee	2016-
Professional Education Committee	2016-2018
Honor Council	2016-2017
Quality Assessment and Improvement Committee	2015-2016
Faculty Search Committee	2016-2018
PBS Chair Search Committee	2016, 2018
Assistant Dean for Assessment search committee	2018

University Institute of Pharmaceutical Sciences, Panjab University

Member, Board of Studies	2004-2005
Academic Secretary	2003-2004
Administrative Secretary	2002-2003
Member, Organizing Committee, 91 st Indian Sciences Congress, Chandigarh.	2004
Member, Organizing Committee, Annual Conference of Indian Pharmacy Graduates Association, Chandigarh.	2003
Member, Organizing Committee, Recent Advances in Drug Discovery and Development workshop, Chandigarh.	2003

TEACHING AND LEARNING

California Health Sciences University 2015-present**PHR635 (Principles of Drug action-III)**Course Director and instructor: 2016, 2017, 2018, 2019Responsibilities: Course design and delivery, assessment and grading, review sessions, block and final exams, soliciting student and faculty feedback.Topics: Pathophysiology and drug therapy of diseases affecting Central Nervous System (CNS)Assessments: RATs, Applications, case studies and projects and poster presentations, block and final examsAccomplishments: **TEACHER OF THE YEAR AWARD: 2015-16, 2017-2018****COURSE OF THE YEAR AWARD: 2017-2018****PHR735 (Principles of drug action-IV)**Instructor: 2017, 2018Course Director and instructor: 2016Responsibilities: Course design and delivery, assessment and grading, review sessions, block and final exams, soliciting student and instructor feedback.Topics: Pathophysiology and drug therapy of diseases affecting GI, Infectious diseases and CancerAssessments: RATs, Applications, case studies and projects and poster presentations, block and final examsAccomplishments: **TEACHER OF THE YEAR AWARD, 2016-17****PHR540: Extemporaneous Compounding and Dispensing**Course Director and instructor: 2016, 2017, 2018Responsibilities: Course design and delivery, assessment and grading, review sessions, block and final exams, soliciting student and instructor feedback.Topics: Pharmaceutical Calculations, Extemporaneous Compounding and Dispensing of Sterile

and non-sterile preparations

Assessments: Lab work, final product, block and final exams

PHR632-Pharmacology II

Instructor: 2015, 2016

PHR511-Biochemistry

Instructor: 2017; 2018

Course Director: 2018

Panjab University, Chandigarh, India

Course director and Instructor: 2002-2005

General Pharmacology, CNS Pharmacology, GI Pharmacology, Infectious Diseases, Endocrine Pharmacology and Experimental Pharmacology Lab

Nalanda College of Pharmacy, India

Instructor: 1997-98

Human Anatomy and Physiology, Pharmacology, Experimental Pharmacology Lab

RESEARCH INTERESTS

NEUROPHARMACOLOGY:

Affective and Neurodegenerative Diseases: Affective disorders: Depression and Anxiety-Endocannabinoid mechanisms in affective disorders. Excitotoxicity and Oxidative stress, Neuroinflammation and cyclooxygenase mediators in the pathophysiology of chronic neurodegenerative disorders like Parkinsonism, Huntington's disease and Alzheimer's disease and associated neuropsychiatric complications (anxiety, depression and psychosis).

Pain and inflammatory disorders: Acute and chronic inflammatory (Rheumatoid arthritis) and neuropathic pain disorders including diabetic peripheral neuropathy. Role of endocannabinoidergic system in acute, chronic, inflammatory and neuropathic pain. Development of endocannabinoid based drugs, particularly fatty acid amide hydrolase inhibitors for the treatment of pain and inflammatory disorders.

FIBROTIC DISORDERS: Role of inflammatory and pro-fibrotic cytokines in the pathophysiology of Idiopathic pulmonary fibrosis; Animal model development for liver and renal fibrosis

RESEARCH GRANTS

1. Development of plant based anti-oxidants for the treatment of drug-induced movement disorders. (Co-Principle Investigator) 2005
University Grants Commission (UGC) Center for Advanced Studies CAS Research Grant, Panjab University, Chandigarh, India
Funding: Rs. 2500000
2. Sertraline in Addition to Standard of Care Treatment for Coccidiomycosis 2016
UCSF-Fresno: Simon Paul, Roger Mortimer, Nathan Stockamp
CHSU: M. Delwar Hussain, Chandra Kolli, Sreenivasulu Pattipati
University of Minnesota: David Boulware
Funding: US\$ 25000

GRADUATE THESIS SUPERVISED

2004-2005 Puneet Kumar (Neuropharmacology)

University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

Title: Neuroprotective Role of Antioxidants and Cyclooxygenase Inhibitors in an Experimental Model of Huntington 's disease In Rats

2004 - 2005 Neha Sehgal (Neuropharmacology)

University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

Title: Pharmacological Investigations on Antioxidants and Cyclooxygenase inhibitors in an Animal Model of Alzheimer's disease in Rats

SCIENTIFIC PUBLICATIONS

Citation indices	All
Citations	3201
h-index	35
i10-index	60

Peer Reviewed Manuscripts

<https://www.ncbi.nlm.nih.gov/pubmed/?term=Naidu+Pattipati>

Original Research Articles:

1. Srikumar BN, **Naidu PS et al.**, Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus. **Journal of psychopharmacology** **2018; 33(1): 25-36.**
2. Marcin LR, Warriar J, Thangathirupathy S, Shi J, Karageorge GN, Pearce BC, Ng A, Park H, Kempson J, Li J, Zhang H, Mathur A, Reddy AB, Nagaraju G, Tonukunuru G, Gupta GVRKM,

- Kamble M, Mannori R, Cheruku S, Jogi S, Gulia J, Bastia T, Sanmathi C, Aher J, Kallem R, Srikumar BN, Vijaya kumar K, **Naidu PS et al.**, BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder. *ACS Med. Chem. Lett.*, 2018, 9 (5), pp 472–477
3. Bristow LJ, Guli J, Weed MR, Srikumar BN, Li Y-W, Graef JD, **Naidu PS et al.**, Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B (GluN2B) Receptor Negative Allosteric Modulator with Potential in Treatment Resistant Depression. *Journal of Pharmacology and Experimental Therapeutics* 2017, 363 (3) 377-393.
 4. BN Srikumar, M Paschapur, ... **Naidu PS et al.**, Characterization of the adrenocorticotrophic hormone-Induced mouse model of resistance to antidepressant drug treatment. *Pharmacol Biochem and Behav.*, 2017: 161:53-61
 5. Louis JV, Lu Y, Pierschl R, Tian Y, Hong Y, Dandapani K, **Naidu PS et al.**, [3H]BMT-046091 a potent and selective radio ligand to determine AAK1 distribution and target engagement. *Neuropharmacology*, 2017; 118: 167-174.
 6. Kostich W, Hamman BD, Li Yu-Wen, **Naidu PS et al.** Inhibition of AAK1 Kinase as a Novel Therapeutic approach to treat neuropathic pain. *Journal of Pharmacology and Experimental Therapeutics*, 2016; 258: 371-386.
 7. Kumar KV, Ruda A, Sreedhara MV, Subramani TS, Prasad DS, Das MA, Li YW, Bristow LJ, **Naidu PS**, Vikradidhyan RK. Bacillus Calmette-Guerin (BCG) Vaccine induced a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice. *Brain, Behavior and Immunity*, 2014; 42: 204-211.
 8. Fowler CJ, Björklund E, Lichtman AH, **Naidu PS**, Congiu C, Onnis V. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. *J Enzyme Inhib Med Chem.* 2013; 28(1):172-82.
 9. Kinsey SG, **Naidu PS**, Cravatt BF, Dudley DT, Lichtman AH. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. *Pharmacol Biochem Behav.* 2011 Oct;99(4):718-25
 10. Kinsey SG, Mahadevan A, Zhao B, Sun H, **Naidu PS**, Razdan RK, Sallwey DE, Imad Damaj M, Lichtman AH. The CB(2) cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. *Neuropharmacology.* 2011 Feb-Mar;60(2-3):244-51
 11. **Naidu PS**, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH. Regulation of inflammatory pain by inhibition of Fatty acid amide hydrolase (FAAH). *Journal of Pharmacology and Experimental Therapeutics*, 2010 Jul;334(1):182-90.
 12. Booker L, **Naidu PS**, Razdan RK, Mahadevan A, Lichtman AH. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. *Drug Alcohol Dependence*, 2009; 105(1): 42-7.
 13. Fowler CJ, **Naidu PS**, Lichtman A, Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. *British Journal of Pharmacology*, 2009; 156(3): 412-9.

14. **Naidu PS**, Booker L, Cravatt BF, Lichtman AH. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. **Journal of Pharmacology and Experimental Therapeutics**, 2009; 329(1): 48-56.
15. Kumar A, Seghal N, Kumar P, Padi SS, **Naidu PS**. Protective effect of quercetin against ICV colchicines-induced cognitive dysfunction and oxidative damage in rats. **Phytotherapy Research** 2008 22(12):1563-69.
16. **Naidu PS**, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD. Antidepressant-like activity of NIH 11082, a selective delta opioid agonist in the mouse tail suspension test. **European Journal of Pharmacology** 2007, 566(1-3): 132-136.
17. Kumar A, **Naidu PS**, Seghal N, Padi SS. Effect of curcumin on intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. **J Med Food**. 2007 Sep;10(3):486-94.
18. Kumar A, Seghal N, **Naidu PS**, Padi SS, Goyal R. Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. **Pharmacol Rep**. 2007; 59(3):274-83.
19. Dhir A, **Naidu PS**, Kulkarni SK. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. **Seizure**. 2007, 16(8): 691-7.
20. Kumar P, Padi SSV, **Naidu PS**, Kumar A. Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. **Fundam Clin Pharmacol**. 2007 Jun;21(3):297-306.
21. **Naidu PS**, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. Inhibition of fatty acid amide hydrolase (FAAH) augments the pharmacological effects of anandamide but lacks efficacy in mouse models of emotionality. **Psychopharmacology** 2007; 192(1): 61-70.
22. Kumar P, Padi SSV, **Naidu PS**, Kumar A. 3-nitropropionic acid-induced neurotoxicity: An Animal model for Huntington's disease. **Journal of Cell and Tissue Research** 2007, 7 (1): 853-860
23. Kumar P, Padi SSV, **Naidu PS**, Kumar A. Possible neuroprotective mechanisms of Curcumin in attenuating 3-Nitropropionic Acid-Induced Neurotoxicity. **Meth Find in Exp Clin Pharm**, 2007 Jan-Feb;29(1):19-25.
24. Kumar A, **Naidu PS**, Seghal N, Padi SSV. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. **Pharmacology** 2007, 79: 17-26
25. Kumar P, Padi SSV, **Naidu PS**, Kumar A. Protective effect of Antioxidants on 3-Nitropropionic acid induced Oxidative Stress and Cognitive Impairment. **Annals of Neuroscience** 2006, 13 (2): 41-47.
26. Kumar A, **Naidu PS**, Seghal N, Padi SSV. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. **European Journal of Pharmacology** 2006, 551(1-3): 58-66.
27. Kumar P, Padi SSV, **Naidu PS**, Kumar A. Effect of resveratrol on 3-NP-induced neurotoxicity, an animal model of Huntington's disease: possible neuroprotective mechanisms. **Behavioral Pharmacology** 2006, 17(5-6): 485-492.
28. Dhir A, **Naidu PS**, Kulkarni SK. Effect of cyclooxygenase inhibitors on pentylenetetrazol(PTZ)-induced convulsions: possible mechanisms of action. **Prog Neuropsychopharmacol Biol Psychiat**, 2006, 30: 1478-1485.

29. Padi SSV, **Naidu PS**, Kulkarni SK. Involvement of peripheral prostaglandins in formalin-induced nociceptive behaviors in the orofacial area of rats. **Inflammopharmacology**. 2006, 14(1-2): 57-61.
30. Dhir A, **Naidu PS**, Kulkarni SK. Effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice. **Fundam Clin Pharmacol**. 2006 Jun; 20(3):255-61.
31. Dhir A, Padi SS, **Naidu PS**, Kulkarni SK. Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. **Eur J Pharmacol**. 2006; 535(1-3):192-8.
32. **Naidu PS**, Singh A, Kulkarni SK. Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. **Phytother Res**. 2006; 20(2):140-6.
33. Dhir A, **Naidu PS**, Kulkarni SK. Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action. **Indian Journal of Experimental Biology**, 2006; 44(4): 286-91.
34. Goel RK, Singh A, Naidu PS, Mahajan MP, Kulkarni SK. PASS assisted search and evaluation of some azetid-2-ones as C.N.S. active agents. **Journal of Pharmacology and Pharmaceutical Sciences**, 2005; 8(2):182-9.
35. Dhir A, **Naidu PS**, Kulkarni SK. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced Behavioural changes. **Addict Biol**. 2005; 10(4):329-35.
36. Joshi D, **Naidu PS**, Singh A, Kulkarni SK. Protective effect of quercetin on alcohol abstinence-induced anxiety and convulsions. **J Med Food**. 2005; 8(3):392-6.
37. Joshi D, **Naidu PS**, Singh A, Kulkarni SK. Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. **Pharmacology**. 2005;75(2):93-7.
38. Dhir A, **Naidu PS**, Kulkarni SK. Effect of naproxen, a non-selective cyclooxygenase inhibitor, on pentylenetetrazol-induced kindling in mice. **Clin Exp Pharmacol Physiol**. 2005; 32(7):574-84.
39. Joshi D, Singh A, **Naidu PS**, Kulkarni SK. Protective effect of bupropion on morphine tolerance and dependence in mice. **Methods Find Exp Clin Pharmacol**. 2004; 26(8):623-6.
40. **Naidu PS**, Kulkarni SK. Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. **Methods Find Exp Clin Pharmacol**. 2004; 26(5):323-6.
41. **Naidu PS**, Singh A, Kulkarni SK. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. **Pharmacology**. 2004; 70(2):59-67.
42. Singh A, **Naidu PS**, Patil CS, Kulkarni SK. Effect of FK506 (tacrolimus) in animal models of inflammation. **Inflammopharmacology**. 2003; 11(3):249-57.
43. Singh A, **Naidu PS**, Kulkarni SK. Reversal of aging and chronic ethanol-induced cognitive dysfunction by quercetin a bioflavonoid. **Free Radic Res**. 2003; 37(11):1245-52.
44. Singh A, **Naidu PS**, Kulkarni SK. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. **Eur J Pharmacol**. 2003; 477(2):87-94.
45. **Naidu PS**, Singh A, Joshi D, Kulkarni SK. Possible mechanisms of action in quercetin reversal of morphine tolerance and dependence. **Addict Biol**. 2003; 8(3):327-36.

46. Singh A, Kumar G, **Naidu PS**, Kulkarni SK. Protective effect of FK506 (tacrolimus) in pentylenetetrazol-induced kindling in mice. **Pharmacol Biochem Behav.** 2003, 75(4): 853-60.
47. Singh A, Kumar G, **Naidu PS**, Kulkarni SK. Antinociceptive action of FK506 in mice. **Indian Journal of Experimental Biology**, 2003; 41(12): 1405-9.
48. **Naidu PS**, Singh A, Kulkarni SK. D2-dopamine receptor and alpha2-adrenoreceptor mediated analgesic response of quercetin. **Indian Journal of Experimental Biology**, 2003; 41(12): 1400-4.
49. Singh A, **Naidu PS**, Kulkarni SK. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats. **Indian Journal of Experimental Biology**, 2003; 41(11): 1264-8.
50. **Naidu PS**, Singh A, Kulkarni SK. Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action. **J Med Food.** 2003, 6(2):107-14.
51. **Naidu PS**, Singh A, Kulkarni SK. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. **Neuropharmacology.** 2003; 44(8):1100-6.
52. Singh A, **Naidu PS**, Kulkarni SK. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. **Pharmacology.** 2003; 68(2):81-8.
53. **Naidu PS**, Singh A, Kulkarni SK. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. **Psychopharmacology (Berl).** 2003; 167(4):418-23.
54. **Naidu PS**, Singh A, Kaur P, Sandhir R, Kulkarni SK. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. **Pharmacol Biochem Behav.** 2003; 74(3):641-8.
55. Singh A, **Naidu PS**, Gupta S, Kulkarni SK. Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. **J Med Food.** 2002, (4):211-20.
56. **Naidu PS**, Kulkarni SK. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. **Prog Neuropsychopharmacol Biol Psychiatry.** 2002; 26(5):819-22.
57. **Naidu PS** and S.K.Kulkarni. Reversal of reserpine-induced vacuous chewing movements by ethanol: Possible GABA-A receptor modulation. **Brain Pharmacology** 2002, 1(4): 189-195.
58. **Naidu PS**, Singh A, Kulkarni SK. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. **Br J Pharmacol.** 2002; 136(2):193-200.
59. **Naidu PS** and S.K.Kulkarni. Dopamine-Glutamate modulation of haloperidol-induced vacuous chewing movements in rats. **Brain Pharmacology** 2002, 1(2): 147-158.
60. **Naidu PS**, Kulkarni SK. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. **Eur J Pharmacol.** 2001; 428(1):81-6.
61. **Naidu PS**, Kulkarni SK. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. **Eur J Pharmacol.** 2001;430(2-3):295-8.
62. Raghavendra V, **Naidu PS**, Kulkarni SK. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. **Brain Res.** 2001; 904(1):149-52.
63. **Naidu PS**, Kulkarni SK. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. **Behav Pharmacol.** 2001; 12(3):209-16.
64. **Naidu PS**, Kulkarni SK. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists. **European Journal of Pharmacol.** 2001; 420(2-3):113-7.
65. Kulkarni SK, **Naidu PS**. Isoniazid-induced orofacial dyskinesia in rats: An experimental model of tardive dyskinesia. **Indian Journal of Pharmacology**, 2001; 33: 286-88.

66. **Naidu PS**, Kulkarni SK. Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements. **Methods Find Exp Clin Pharmacol**. 2000; 22(10):747-51.

Review Articles:

1. Kumar A, Mittal R, **Naidu PS**. Insulin Resistance: Recent Advances in Pathogenesis, Molecular Mechanisms and Clinical Relevance. **EC Pharmacology and Toxicology** 4.6 (2017): 244-262
2. Kumar A, Aggarwal R, Singh A, **Naidu PS**. Animal Models in Drug Discovery of Alzheimer's disease: A Mini Review. **EC Pharmacology and Toxicology** 2.1 (2016): 60-79.
2. Kumar P, **Naidu PS**, Padi SSV, Kumar A. Huntington's disease: A Review. **J Pharmacet Edu Res** 2007; 41(4): 287-294.
3. Kulkarni SK, **Naidu PS**. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. **Drugs Today (Barc)**. 2003; 39(1):19-49.
4. Kulkarni SK, **Naidu PS**. Animal models of tardive dyskinesia--a review. **Indian J Physiol Pharmacol**. 2001; 45(2):148-60.
5. Kulkarni SK, **Naidu PS**. Tardive dyskinesia: An update. **Drugs Today (Barc)**. 2001; 37(2):97-119.

Book Chapter:

1. Kulkarni SK, Dhir A, **Naidu PS**. Cyclooxygenase as the novel drug target(s) in CNS related disorders. Ed. Mathur R. In **Pain Updated**: Anamaya Publishers, New Delhi, India. 2006; pp 258-270.

Peer-reviewed research abstracts and POSTER presentations:

1. **P.S.NAIDU*** and S.K.Kulkarni. Rat model of tardive dyskinesia: Role of serotonergic and glutamatergic modulation. **Indian Pharmaceutical Congress, 1999, Indore, India**.
2. S.K.Kulkarni and **P.S.NAIDU***. Animal models of tardive dyskinesia: Neurotransmitter mechanisms. **CME on new drug development in neuropsychiatric disorders: Relevance to clinical practice, 2000, IHBAS, New Delhi, India**.
3. **P.S.NAIDU*** and S.K.Kulkarni. Serotonergic involvement in neuroleptic-induced orofacial dyskinesia in rats. **Indian Pharmaceutical Congress, 2000, Hyderabad, India**.
4. **P.S.NAIDU*** and S.K.Kulkarni. Serotonergic involvement in reserpine-induced orofacial dyskinesia in rats. **XXXIII Annual conference of Indian Pharmacological Society, 2000, Gandhinager, India**.
5. **P.S.NAIDU*** and S.K.Kulkarni. Possible antioxidant mechanisms in carvedilol reversal of neuroleptic-induced orofacial dyskinesia. **53rd Indian Pharmaceutical Congress, 2001, New Delhi, India**.
6. **P.S.NAIDU*** and S.K.Kulkarni. Reversal of haloperidol-induced orofacial dyskinesia by cyclooxygenase inhibitors. **XXXIV Annual Conference of Indian Pharmacological Society, 2002, Nagpur**
7. S.K.Kulkarni* and **P.S.NAIDU**. Recent developments in tardive dyskinesia research. 2001, Jordan. **5th Scientific Congress of the Association of the Colleges of Pharmacy in the Arab World & 2nd International Conference of the Faculty of Pharmacy, Amman, Jordan**.
8. S.K.Kulkarni* and **P.S.NAIDU**. Melatonin attenuates haloperidol-induced orofacial dyskinesia: Possible antioxidant mechanisms. **CINP Congress, 2002, Montreal, Canada**.
9. **P.S.NAIDU*** and S.K.Kulkarni. Quercetin reversal of haloperidol-induced orofacial dyskinesia: Possible antioxidant mechanisms. **7th International Conference on Parkinson's Disease and Movement Disorders, 2002, Miami, Florida, USA**

10. S.K.Kulkarni* and **P.S.NAIDU**. Attenuation of haloperidol-induced orofacial dyskinesia by cyclooxygenase inhibitors. **7th International Conference on Parkinson's Disease and Movement Disorders, 2002 Miami, Florida, USA**
11. **P.S.NAIDU**, A.Singh, S.K.Kulkarni. Effect Of *Withania somnifera* Root Extract On Haloperidol-Induced Orofacial Dyskinesia: Possible Mechanisms Of Action. **35th Annual conference of Indian Pharmacological Society, 2002, Gwalior, India.**
12. S.K.Kulkarni and **P.S.NAIDU**. An Insight into Tardive dyskinesia. **35th Annual conference of Indian Pharmacological Society, 2002, Gwalior, India.**
13. A.Singh, **P.S.NAIDU**, S.K.Kulkarni. *Withania somnifera* as an effective adjuvant to L-dopa in drug-induced catatonia. **35th Annual conference of Indian Pharmacological Society, 2002, Gwalior, India.**
14. D. Joshi, A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Reversal of Diazepam tolerance and withdrawal-induced hyperactivity and anxiety by Quercetin, a Bioflavonoid. **35th Annual conference of Indian Pharmacological Society, 2002, Gwalior, India.**
15. G. Kumar, A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Role of quercetin in PTZ-induced kindling in mice. **35th Annual conference of Indian Pharmacological Society, 2002, Gwalior, India.**
16. **P.S.NAIDU**, A.Singh, S.K.Kulkarni. Quercetin, A Bioflavonoid attenuates haloperidol-induced orofacial dyskinesia: Possible antioxidant mechanisms. **54th Indian Pharmaceutical Congress, 2002, Pune, India.**
17. A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Effect of natural and synthetic antioxidants in mouse model of chronic fatigue syndrome. **54th Indian Pharmaceutical Congress, 2002, Pune, India**
18. **P.S.NAIDU**, A.Singh, S.K.Kulkarni. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by *Withania somnifera* root extract. **International Conference On Role Of Free Radicals And Antioxidants In Health & Disease And II Annual conference of SFRR-India 2003, Lucknow, India.**
19. A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Natural antioxidants as effective adjuvants in drug-induced catalepsy. **International Conference On Role Of Free Radicals And Antioxidants In Health & Disease And II Annual conference of SFRR-India 2003, Lucknow, India.**
20. G. Kumar, A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Protective effect of FK506 (Tacrolimus) in pentylenetetrazole-induced kindling in mice. **International Conference On Role Of Free Radicals And Antioxidants In Health & Disease And II Annual conference of SFRR-India 2003, Lucknow, India.**
21. D. Joshi, A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Reversal of diazepam tolerance and withdrawal-induced hyperactivity and anxiety in mice by melatonin. **International Conference On Role Of Free Radicals And Antioxidants In Health & Disease And II Annual conference of SFRR-India 2003, Lucknow, India.**
22. **P.S.NAIDU**, A.Singh, S.K.Kulkarni. Antioxidant reversal of haloperidol-induced orofacial dyskinesia and cognitive dysfunction. **6th IBRO World Congress of Neuroscience, 2003, Prague, Czech Republic.**
23. **P.S.NAIDU**, A.Singh, S.K.Kulkarni. Possible role of COX-2 in lipopolysaccharide potentiation of perphenazine-induced catalepsy in mice. **6th World Congress on Inflammation, 2003, Vancouver, Canada.**
24. A.Singh, **P.S.NAIDU**, S.K.Kulkarni. Effect of FK506 in animal models of inflammation. **6th World Congress on Inflammation, 2003, Vancouver, Canada.**
25. **S.N. Pattipati**, A. Singh, S.K. Kulkarni. Reversal by melatonin of reserpine-induced orofacial dyskinesia and memory dysfunction in rats. **7TH congress of the European Federation of Neurological Societies, 2003, Helsinki, Finland.**
26. A. Singh, **S.N. Pattipati**, S.K. Kulkarni. Reversal of aging and chronic ethanol-induced cognitive dysfunction by Quercetin. **7TH congress of the European Federation of Neurological Societies, 2003, Helsinki, Finland.**
27. A. Dhir, **P.S. Naidu** and S.K. Kulkarni. Role of Cyclooxygenase inhibitors on amphetamine and MK-801 induced hyperlocomotion. **International Symposium on Recent Advances in Pharmacology, 2004, New Delhi, India.**

28. A. Dhir, **P.S. Naidu** and S.K. Kulkarni. Role of cyclooxygenase inhibitors in epilepsy. **36th Annual Conference of Indian pharmacological society (IPS), 2003, Delhi, India.**
29. S.K. Kulkarni and **P.S. Naidu**. Tardive Dyskinesia: An oxidative stress-induced neurodegeneration. **International Symposium on Recent Advances in Pharmacology, 2004, New Delhi, India.**
30. **P.S. Naidu**, A. Singh and S.K. Kulkarni. **Reversal by FK506 of reserpine-induced orofacial dyskinesia and cognitive dysfunction. International Conference on Schizophrenia (ICONS) 2004, Chennai, India.**
31. Kumar, **P.S. Naidu** and S.K. Kulkarni. Effect of *Withania somnifera* root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. **International Conference on Schizophrenia (ICONS) 2004, Chennai, India.**
32. P.S.V. Satyanarayana, **P.S. Naidu** and S.K. Kulkarni. Rofecoxib reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction. **International Conference on Schizophrenia (ICONS) 2004, Chennai, India.**
33. A. Dhir, **P.S. Naidu** and S.K. Kulkarni. Effect of Cyclooxygenase inhibitors on apomorphine induced stereotypy and hyperlocomotion. **International Conference on Schizophrenia (ICONS) 2004, Chennai, India.**
34. **P.S.Naidu** and S.K.Kulkarni. Antioxidants ameliorated reserpine-induced orofacial dyskinesia and cognitive dysfunction. **6th Biennial meeting of the Asian-Oceanian society for Neurochemistry annual meeting, 2004, Hong Kong, China.**
35. **P.S.Naidu** and S.K.Kulkarni. Reversal by tacrolimus (FK-506) of reserpine-induced orofacial dyskinesia and memory dysfunction in rats. **Symposium on Neural plasticity, Development and Repair, 2004, Hong Kong, China.**
36. **P.S. Naidu**, A. Singh and S.K. Kulkarni. Cyclooxygenase Inhibitors Reverses Haloperidol-Induced Orofacial Dyskinesia and Cognitive Dysfunction. **59th Annual meeting of the Society of Biological Psychiatry, 2004, New York, USA.**
37. A. Dhir, **P.S. Naidu** and S.K. Kulkarni. Protective effect of COX-inhibitors in ethanol-induced withdrawal symptoms. **International Neuroscience conference, 2004, Hyderabad, India.**
38. **P.S. Naidu**, A. Singh and S.K. Kulkarni. Attenuation of reserpine-induced perioral movements and memory dysfunction by natural antioxidants. **2nd Symposium of Federation of Asian-Oceanic Neuroscience Societies (FAONS) and 3rd Iranian Neuroscience Congress, 2004, Tehran, Iran.**
39. S.K. Kulkarni and **P.S. Naidu**. Oxidative stress and tardive dyskinesia: role of natural antioxidants. **2nd Symposium of Federation of Asian-Oceanic Neuroscience Societies (FAONS) and 3rd Iranian Neuroscience Congress, 2004, Tehran, Iran.**
40. **P.S. Naidu**, A. Singh and S.K. Kulkarni. Nimesulide a preferential cyclooxygenase-2 inhibitor ameliorates antipsychotic-induced orofacial dyskinesia and cognitive dysfunction. **Pharmaceutical Sciences World Congress (PSWC), 2004, Kyoto, Japan.**
41. A. Kumar, A. Dhir, **S.N. Pattipati**, S.K. Kulkarni. Cyclooxygenase inhibitors ameliorate PTZ-induced convulsions in mice. **5th Asian & Oceanian Epilepsy congress 2004, Bangkok, Thailand.**
42. **S.N. Pattipati** and A. Singh and Kulkarni SK. Cyclooxygenase inhibitors attenuate haloperidol-induced orofacial dyskinesia and cognitive dysfunction. **XXV CIMP Congress, 2004, Paris, France.**
43. **Pattipati S**, Singh A, Kulkarni S. Melatonin Reversal of antipsychotic-induced orofacial dyskinesia and cognitive dysfunction. **Federation of European Neuroscience Societies (FENS) forum 2004, Lisbon, Portugal.**
44. **S.N. Pattipati** and A. Singh and Kulkarni SK. Celecoxib, A Selective Cyclooxygenase-2 Inhibitor Ameliorates Antipsychotic-Induced Perioral Movements and Associated Memory Dysfunction. **Neuroscience 2004, San Diego, USA.**
45. **S.N. Pattipati** and Shrinivas K. Kulkarni. U74500A, a 21-Aminosteroid Ameliorates antipsychotic-induced orofacial dyskinesia and memory dysfunction. **Society of Biological Psychiatry Annual conference, 2005, Atlanta, GA.**

46. **S.N. Pattipati**, N. Sehgal, A. Kumar. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced cognitive impairment and oxidative stress. **Neuroscience 2005, Washington DC.**
47. **S.N. Pattipati** and Aron H. Lichtman. Inhibition of FAAH produces CB1 receptor mediated anti-hyperalgesic effects in collagen-induced arthritic pain. **International Cannabinoid Research Society conference, 2006, Tihany, Hungary.**
48. **S.N.Pattipati**, S.A. Varvel, B.F. Cravatt, B.R. Martin, A.H. Lichtman, Inhibition of fatty acid amide hydrolase (FAAH) augments the pharmacological effects of anandamide but lacks efficacy in mouse models of emotionality. **XXVI CINP congress 2006, Chicago, USA**
49. **S.N.Pattipati**, A.H. Lichtman. Inhibition of FAAH produces CB2 receptor mediated anti-inflammatory effects in lipopolysaccharide (LPS)-induced paw inflammation. **Neuroscience 2006, Atlanta, GA.**
50. **S.N.Pattipati**, A.H. Lichtman. Synergistic antinociceptive effects of URB597 and diclofenac in a mouse visceral pain model. **International Cannabinoid Research Society conference 2007, Saint-Sauv ur, Canada.**
51. **S.N.Pattipati**, D.Duddley, B.Cravatt, BR. Martin, A.H. Lichtman. Fatty Acid Amide Hydrolase Is a Viable Target to Reduce Collagen-Induced Arthritis and Pain. **Neuroscience 2007, San Diego, CA.**

HONORS AND AWARDS

- 2018 Course Director, P-2 **Course of the Year Award**, California Health Sciences University, Clovis, CA, USA
- 2018 **Teacher of the Year Award**, California Health Sciences University, Clovis, CA, USA
- 2017 **Teacher of the Year Award**, California Health Sciences University, Clovis, CA, USA
- 2016 **Teacher of the Year Award**, California Health Sciences University, Clovis, CA, USA
- 2015 Bristol-Myers Squibb **R&D STAR AWARD**
- 2014 Bristol-Myers Squibb **R&D STAR AWARD**
- 2013 Bristol-Myers Squibb **R&D Excellence Award** for exhibiting the BMS Biopharma Core Behaviors
- 2011 Bristol-Myers Squibb **R&D Star award** for Scientific Excellence and Leadership
- 2010 Bristol-Myers Squibb **R&D STAR AWARD**
- 2007 International **Cannabinoid Research Society (ICRS) Travel Award** for attending ICRS conference, Saint-Sauveur, Canada, 2007
- 2006 Central Virginia Chapter of Society for Neuroscience Postdoctoral Travel Award
- 2006 Biography listed in **Marquis Who's Who of Emerging Leaders in Asia 2007**
- 2006 Biography listed in **Prestige International Who's Who Registries of Outstanding Professionals 2006**
- 2006 International **Cannabinoid Research Society (ICRS) Travel Award** for attending ICRS conference, Tihany, Hungary, 24-28 June 2006
- 2006 Biography listed in **Marquis Who's Who in the World 2006**
- 2005 **International Brain Research Organization (IBRO) Travel Award** for attending World Congress on Huntington's disease, Manchester, UK 11-13th September, 2005.
- 2005 **Huntington's disease Society's International Travel Award** for attending World Congress on Huntington's disease, Manchester, UK 11-13th September, 2005.

- 2005 **Society of Biological Psychiatry's (SOBP) International Travel Fellowship** and invited to participate in Society of Biological Psychiatry's Annual conference-2005, Atlanta, 19th May to 21st May, 2005
- 2005 **International Behavioral Neuroscience Society (IBNS) Travel Award**, New Mexico, USA, May 29-1st June 2005.
- 2005 **International society for Neurochemistry (ISN) travel award** to participate in ISN/ESN conference, Innsbruck, Austria, 21-26 August 2005,
- 2004 Awarded **Prestigious Rafelson Young Investigator Award by International College of Neuropsychopharmacology (CINP), USA, 2004.**
- 2004 **IBRO International travel fellowship** to attend the Society for Neuroscience 34th Annual Meeting, San Diego, 2004, USA.
- 2004 **Society of Biological Psychiatry's (SOBP) International Travel Fellowship** and invited to participate in Society of Biological Psychiatry's Annual conference-2004, New York, 29th April to 1st May, 2004
- 2004 **Department of Science and Technology, Govt. of India** Travel fellowship
- 2004 **All India Council of Technical Education travel fellowship** to attend the 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy from 12-17th June, 2004
- 2004 **Received Best Poster Award** at 2nd Symposium of the Federation of Asian-Oceanic Neuroscience Societies (FAONS) and 3rd Iranian Neuroscience Congress, Tehran, Iran from May 16-19th 2004.
- 2004 Indian National Science Academy travel fellowship (INSA)
- 2004 IBRO-APRC/FAONS Travel Fellowship to attend **Federation of Asian-Oceanic Neuroscience Societies (FAONS)** symposium, Tehran, The Islamic Republic of Iran.
- 2004 **Best poster award** at International Congress on Schizophrenia, held at Chennai, India
- 2004 **Special IBRO fellowship** and invited to participate in the IBRO neuroscience school-2004 **(imaging techniques including immunohistochemistry and confocal microscopy)**, Hong Kong, 2004
- 2004 **Bester poster Award** at International symposium on Recent Advances in Pharmacology, New Delhi, India
- 2003 Asian-Pacific Society for Neurochemistry's (APSN) travel award to attend **The 6th Biennial Meeting of the Asian-Pacific Society for Neurochemistry** February 04-07, 2004, Hong Kong, China.
- 2003 **SFN/IBRO travel award** to attend the **Society for Neuroscience 33rd Annual Meeting**, New Orleans, USA.
- 2003 International Association of Inflammation Societies (IAIS) Young Investigator Award
- 2003 **International Brain Research Organization (IBRO)** travel grant to attend **6th IBRO word congress**, Prague, Czech Republic.

- 2002 Council of Scientific and Industrial Research (CSIR), Govt. of India, Travel Grant to attend **7th International Congress on Parkinson's disease and Movement Disorders**, Miami, USA.
- 2001 Council of Scientific and Industrial Research (CSIR), **Senior Research Fellowship**, Govt. of India, New Delhi.
- 2000 **Ranked 1st** in the discipline and overall 4th in MS (Pharm) Examination, Panjab University.
- 1998 University Grants Commission (UGC), **Junior Research fellowship**, Govt. of India, New Delhi.
- 1998 **IDMA (Indian Drug Manufacturer's Association) G.P.Nair Gold Medal award** for securing highest marks in the BS (Pharm) examination, Kakatiya University.
- 1997 **Ranked 8th (All India) and 1st (South India)** in GATE-97 conducted by IIT Madras with **percentile score 99.49**
- 1997 Gold Medal** for securing highest marks in Pharmacology in BS (Pharm) (Kakatiya University, AP, India).
- 1993 Gold Medal** for standing first in the Diploma in Pharmacy, examination (State Board of Technical Education and Training, AP)

COMMUNITY SERVICE

CHSU Health Fair, 2016, 2017

High school students on campus compounding activity, 2015, 2016, 2017, 2018

ROAD conference, 2016, 2017

STEM Conference 2016, 2017, 2018

HEAL Conference, 2017, 2018

PROFESSIONAL AFFILIATION

- American Association of Colleges of Pharmacy (AACP)
- American Association of Pharmaceutical Scientists (AAPS)
- International Brain Research Organization (IBRO)
- Indian Pharmacological Society
- Indian Academy of Neurosciences
- Parkinson Disease Foundation of India
- World Association of Young Scientists

JOURNAL EDITORIAL BOARD MEMBER or REVIEWER

- EC Pharmacology and Toxicology (<https://www.econicon.com/ECPT-EB.php>)
- Journal of Neurology and Stroke (<http://medcraveonline.com/JNSK/editorial-board>)
- Journal of Pharmacology and Experimental Therapeutics
- Journal of neuroinflammation

- Brain Research
- Psychopharmacology
- Pharmacology, Biochemistry, Behavior
- Indian Journal of Pharmacology
- BMC Pharmacology
- Journal of Medicinal Food
- Journal of Clinical and Diagnostic Research
- Journal of Pharmacopuncture